{"id":"https://openalex.org/W4389230978","doi":"https://doi.org/10.1182/blood-2023-189446","title":"Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes","display_name":"Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes","publication_year":2023,"publication_date":"2023-11-02","ids":{"openalex":"https://openalex.org/W4389230978","doi":"https://doi.org/10.1182/blood-2023-189446"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2023-189446","doi":"https://doi.org/10.1182/blood-2023-189446","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-189446","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102705548","display_name":"Jacqueline Suen Garcia","orcid":"https://orcid.org/0000-0003-2118-6302","observed_orcids":["https://orcid.org/0000-0003-2118-6302","https://orcid.org/0000-0002-2599-7308"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacqueline S. Garcia","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079124367","display_name":"Uwe Platzbecker","orcid":"https://orcid.org/0000-0003-1863-3239","observed_orcids":["https://orcid.org/0000-0003-1863-3239"]},"institutions":[{"id":"https://openalex.org/I4210125843","display_name":"University Hospital Leipzig","ror":"https://ror.org/028hv5492","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210125843"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Uwe Platzbecker","raw_affiliation_strings":["2Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University Medical Center Leipzig, Leipzig, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University Medical Center Leipzig, Leipzig, Germany","institution_ids":["https://openalex.org/I4210125843"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060015628","display_name":"Olatoyosi M. Odenike","orcid":"https://orcid.org/0000-0002-4027-4124","observed_orcids":["https://orcid.org/0000-0002-4027-4124"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4390039251","display_name":"University of Chicago Medicine Comprehensive Cancer Center","ror":"https://ror.org/042wftp98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865","https://openalex.org/I4390039251"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olatoyosi Odenike","raw_affiliation_strings":["3The University of Chicago Medicine and Comprehensive Cancer Center, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3The University of Chicago Medicine and Comprehensive Cancer Center, Chicago, IL","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4390039251"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009044574","display_name":"Shaun A. Fleming","orcid":"https://orcid.org/0000-0002-9734-5616","observed_orcids":["https://orcid.org/0000-0002-9734-5616"]},"institutions":[{"id":"https://openalex.org/I2801993434","display_name":"The Alfred Hospital","ror":"https://ror.org/01wddqe20","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2801993434","https://openalex.org/I4210163178"]},{"id":"https://openalex.org/I4210163178","display_name":"Alfred Health","ror":"https://ror.org/04scfb908","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210163178"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Shaun Fleming","raw_affiliation_strings":["4Alfred Health, Melbourne, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Alfred Health, Melbourne, Australia","institution_ids":["https://openalex.org/I2801993434","https://openalex.org/I4210163178"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050688377","display_name":"Chun Yew Fong","orcid":"https://orcid.org/0000-0001-5773-103X","observed_orcids":["https://orcid.org/0000-0001-5773-103X"]},"institutions":[{"id":"https://openalex.org/I4210163497","display_name":"Austin Health","ror":"https://ror.org/05dbj6g52","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210163497"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Chun Yew Fong","raw_affiliation_strings":["5Department of Hematology, Austin Health, Heidelberg, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Department of Hematology, Austin Health, Heidelberg, Australia","institution_ids":["https://openalex.org/I4210163497"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070277385","display_name":"Rachel J. Cook","orcid":"https://orcid.org/0000-0001-7005-036X","observed_orcids":["https://orcid.org/0000-0001-7005-036X"]},"institutions":[{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachel Cook","raw_affiliation_strings":["6Oregon Health and Science University, Portland, OR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Oregon Health and Science University, Portland, OR","institution_ids":["https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114046358","display_name":"Meagan A. Jacoby","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meagan Jacoby","raw_affiliation_strings":["7Washington University-School of Medicine, St. Louis, MO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Washington University-School of Medicine, St. Louis, MO","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055601574","display_name":"Daniel Nowak","orcid":"https://orcid.org/0000-0001-7130-7921","observed_orcids":["https://orcid.org/0000-0001-7130-7921"]},"institutions":[{"id":"https://openalex.org/I223822909","display_name":"Heidelberg University","ror":"https://ror.org/038t36y30","country_code":"DE","type":"education","lineage":["https://openalex.org/I223822909"]},{"id":"https://openalex.org/I4387153978","display_name":"Medizinische Fakult\u00e4t Mannheim","ror":"https://ror.org/02m1z0a87","country_code":"DE","type":"education","lineage":["https://openalex.org/I4387153978"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Daniel Nowak","raw_affiliation_strings":["8Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany","institution_ids":["https://openalex.org/I223822909","https://openalex.org/I4387153978"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066196706","display_name":"Brenda Chyla","orcid":"https://orcid.org/0000-0003-2594-9696","observed_orcids":["https://orcid.org/0000-0003-2594-9696"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brenda Chyla","raw_affiliation_strings":["9AbbVie Inc, North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9AbbVie Inc, North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060552570","display_name":"Ying Yin Zhou","orcid":"https://orcid.org/0000-0001-8992-7897","observed_orcids":["https://orcid.org/0000-0001-8992-7897"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ying Zhou","raw_affiliation_strings":["9AbbVie Inc, North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9AbbVie Inc, North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052845814","display_name":"Grace Ku","orcid":"https://orcid.org/0000-0001-7808-1769","observed_orcids":["https://orcid.org/0000-0001-7808-1769"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Grace Ku","raw_affiliation_strings":["10Genentech Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Genentech Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091254943","display_name":"Jalaja Potluri","orcid":"https://orcid.org/0000-0002-1146-8253","observed_orcids":["https://orcid.org/0000-0002-1146-8253"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jalaja Potluri","raw_affiliation_strings":["9AbbVie Inc, North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9AbbVie Inc, North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5061026876","display_name":"Guillermo Garcia\u2010Manero","orcid":"https://orcid.org/0000-0002-3631-2482","observed_orcids":["https://orcid.org/0000-0002-3631-2482"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guillermo Garcia-Manero","raw_affiliation_strings":["11University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":15,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5000,"currency":"USD","value_usd":5000},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"142","issue":"Supplement 1","first_page":"319","last_page":"319"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.996999979019165},{"id":"https://openalex.org/keywords/azacitidine","display_name":"azacitidine","score":1.0},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9079999923706055},{"id":"https://openalex.org/keywords/higher-risk-mds","display_name":"high-risk MDS","score":0.8399999737739563},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.7860000133514404},{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.8389999866485596},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7720000147819519},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.9470000267028809},{"id":"https://openalex.org/keywords/hematologic-improvement","display_name":"hematologic improvement","score":0.5379999876022339},{"id":"https://openalex.org/keywords/transfusion-independence","display_name":"transfusion independence","score":0.8029999732971191},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.621999979019165},{"id":"https://openalex.org/keywords/aml-transformation","display_name":"AML transformation","score":0.675000011920929},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.5860000252723694},{"id":"https://openalex.org/keywords/antibiotic-prophylaxis","display_name":"antibiotic prophylaxis","score":0.6690000295639038},{"id":"https://openalex.org/keywords/ipss-r-risk-stratification","display_name":"IPSS-R risk stratification","score":0.6330000162124634},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.46799999475479126}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8579932451248169},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.7690341472625732},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6720322370529175},{"id":"https://openalex.org/C9583187","wikidata":"https://www.wikidata.org/wiki/Q7919510","display_name":"Ven","level":2,"score":0.6457253694534302},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.6199495196342468},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.6036005616188049},{"id":"https://openalex.org/C2780240888","wikidata":"https://www.wikidata.org/wiki/Q6052586","display_name":"International Prognostic Scoring System","level":4,"score":0.5803285837173462},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.490896999835968},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.4755285084247589},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4688364565372467},{"id":"https://openalex.org/C2780235182","wikidata":"https://www.wikidata.org/wiki/Q1181878","display_name":"Decitabine","level":5,"score":0.43906068801879883},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.41995760798454285},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.4013892114162445},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3629099130630493},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3382566273212433},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1446147859096527},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.09779411554336548},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C38652104","wikidata":"https://www.wikidata.org/wiki/Q3510521","display_name":"Computer security","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2023-189446","doi":"https://doi.org/10.1182/blood-2023-189446","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-189446","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4405177971","https://openalex.org/W3197688599","https://openalex.org/W2990177100","https://openalex.org/W4389229339","https://openalex.org/W3095116203","https://openalex.org/W2891110841","https://openalex.org/W3211403252","https://openalex.org/W7118013684","https://openalex.org/W7214647838","https://openalex.org/W4283326755"],"abstract_inverted_index":{"Introduction:":[0],"Azacitidine":[1],"(Aza)":[2],"has":[3],"been":[4],"shown":[5,296],"to":[6,19,60,183,222,227,234,421,595,601,656],"prolong":[7],"survival":[8,216,658],"in":[9,26,54,63,67,78,94,250,263,297,414,480,523,557,575,581,633,637],"patients":[10,79,107,264,281,294,309,408,429,503,513,560,641],"with":[11,38,65,80,85,110,128,350,373,510,628,642],"treatment-naive,":[12],"higher-risk":[13],"myelodysplastic":[14],"syndrome":[15],"(HR":[16],"MDS)":[17],"compared":[18],"lower-intensity,":[20],"conventional":[21],"treatment":[22,46,224,325],"regimens;":[23],"however,":[24],"improvement":[25,203,476],"clinical":[27],"outcomes":[28],"are":[29,295],"needed.":[30],"Clinical":[31],"data":[32,77],"on":[33,153,164,168],"the":[34,45,51,88,95,100,118,185,286,334,418,586],"synergy":[35],"of":[36,47,99,126,136,174,219,269,276,308,324,337,355,378,385,455,483,512,525,529,559,577,583,631,640,651],"Aza":[37,66,157,623],"venetoclax":[39],"(Ven)-a":[40],"selective,":[41],"potent":[42],"BCL-2":[43],"inhibitor-in":[44],"myeloid":[48,229],"malignancies":[49],"and":[50,75,138,156,172,210,232,253,316,448,463,470,487,497,550,569,598,635],"unmet":[52],"need":[53],"HR":[55,69,82,114,644],"MDS":[56,83,115],"provide":[57],"a":[58,351],"rationale":[59],"evaluate":[61],"Ven":[62,148,616],"combination":[64,624,653],"treatment-naive":[68,81,113],"MDS.":[70,645],"Here,":[71],"we":[72],"report":[73],"efficacy":[74],"safety":[76,96],"treated":[84,293],"Ven+Aza":[86,284],"at":[87,144,285,438],"recommended":[89,254],"Phase":[90,101,648],"2":[91,160],"dose":[92,268],"(RP2D)":[93],"expansion":[97],"part":[98],"1b":[102],"study":[103,270,439,608,650],"(NCT02942290).":[104],"Methods:":[105],"Adult":[106],"were":[108,238,248,435,532,561,573,593,613],"enrolled":[109],"de":[111],"novo":[112],"defined":[116],"by":[117,240],"Revised":[119],"International":[120,241],"Prognostic":[121],"Scoring":[122],"System":[123],"(IPSS-R)":[124],"score":[125],">3":[127],"an":[129,374],"Eastern":[130],"Cooperative":[131],"Oncology":[132],"Group":[133,243],"performance":[134],"status":[135],"\u22642,":[137],"bone":[139],"marrow":[140,195],"(BM)":[141],"blasts":[142],"<20%":[143],"baseline.":[145],"Patients":[146],"received":[147,266,283,409,431],"400":[149,617],"mg":[150,618],"orally":[151],"daily":[152],"Days":[154,165,169],"1-14":[155],"75":[158],"mg/m":[159],"intravenously":[161],"or":[162,167,312],"subcutaneously":[163],"1-7":[166],"1-5,":[170],"8,":[171],"9":[173],"each":[175],"28-day":[176],"cycle":[177],"(RP2D).":[178],"The":[179],"primary":[180],"objective":[181],"was":[182,261,302,329,345,367,394,400,423,444,458,478,625],"assess":[184],"complete":[186],"remission":[187],"(CR)":[188],"rate.":[189],"Key":[190,288],"secondary":[191],"objectives":[192],"included":[193,490],"determining":[194],"CR":[196,343,353,393],"(mCR),":[197],"overall":[198,215,474],"response":[199],"rate":[200,344,443],"(ORR),":[201],"hematologic":[202,475],"(HI),":[204],"postbaseline":[205],"red":[206],"blood":[207],"cell":[208],"(RBC)":[209],"platelet":[211,494],"transfusion":[212],"independence":[213],"(TI),":[214],"(OS),":[217],"duration":[218,354,454],"CR,":[220],"time":[221,233,420],"next":[223],"(TTNT),":[225],"transformation":[226],"acute":[228],"leukemia":[230],"(AML),":[231],"AML":[235],"transformation.":[236],"Responses":[237],"assessed":[239],"Working":[242],"2006":[244],"criteria.":[245],"Prophylactic":[246],"antibiotics":[247],"mandated":[249],"Cycle":[251],"1":[252],"for":[255,291,392,446,450,468,619],"Grade":[256,553],"\u22653":[257,516,554],"neutropenia":[258,537,542,562,567],"thereafter.":[259],"Safety":[260],"analyzed":[262],"who":[265,430],"\u22651":[267,505],"treatment.":[271],"Results:":[272],"At":[273,333],"thedata":[274],"cutoff":[275],"May":[277],"31,":[278],"2023,":[279],"107":[280],"had":[282,310,318],"RP2D.":[287],"baseline":[289],"characteristics":[290],"all":[292],"Table":[298,363],"1A.":[299],"Median":[300,322,365,390,396,452],"age":[301],"68":[303],"years":[304],"(range,":[305,331,426,461,466],"26-87),":[306],"64%":[307],"intermediate":[311],"poor":[313],"cytogenetic":[314],"risk,":[315],">89%":[317],"\u22655%":[319],"BM":[320],"blasts.":[321],"number":[323],"cycles":[326],"before":[327],"transplantation":[328,399,413,422,432],"3.0":[330],"1.0-11.0).":[332],"median":[335,352,419],"follow-up":[336],"31.9":[338],"months":[339,357,369,402,425,460,465],"(95%":[340,347,358,370,380,387,403],"CI,":[341,348,359,371,381,388,404],"30.4-42.5),":[342],"29.9%":[346],"21.4-39.5),":[349],"16.6":[356],"10.0-not":[360],"reached":[361],"[NR],":[362],"1B).":[364],"OS":[366,377,384,391],"26":[368],"18.1-51.5),":[372],"estimated":[375],"12-month":[376],"71.2%":[379],"61.4-78.9)and":[382],"24-month":[383],"51.3%":[386],"41.2-60.5).":[389],"NR.":[395],"TTNT":[397],"including":[398,412,579],"6.8":[401],"5.6-8.3).":[405],"Sixty-two":[406],"(57.9%)":[407],"subsequent":[410],"treatment,":[411],"42":[415],"(39.3%)":[416],"patients;":[417],"4.8":[424],"1.4-16.8).":[427],"Among":[428],"post-study,":[433],"17":[434],"transplant":[436],"ineligible":[437],"entry.":[440],"Postbaseline":[441,473],"TI":[442,456],"61.7%":[445],"RBC":[447,469],"72.0%":[449],"platelets.":[451],"maximal":[453],"achieved":[457,479],"5.4":[459,464],"1.8-50.8)":[462],"1.9-56.0)":[467],"platelets,":[471],"respectively.":[472],"(HI)":[477],"51":[481],"(49.0%)":[482],"104":[484],"evaluable":[485],"patients,":[486,578],"specific":[488],"responses":[489,630],"erythroid":[491],"(40/93;":[492],"43.0%),":[493],"(32/74;":[495],"43.2%)":[496],"neutrophil":[498],"(10/57;":[499],"17.5%)":[500],"indices.":[501],"All":[502],"experienced":[504],"treatment-emergent":[506],"adverse":[507,519,602],"event":[508],"(TEAE),":[509],"94.4%":[511],"reporting":[514],"grade":[515,531],"TEAEs.":[517],"Serious":[518],"events":[520],"(SAEs)":[521],"occurred":[522],"68.2%":[524],"patients.":[526,584],"Common":[527],"TEAEs":[528,555],"any":[530],"constipation":[533],"(53.3%),":[534],"nausea":[535],"(49.5%),":[536],"(48.6%),":[538,563],"thrombocytopenia":[539,564],"(44.9%),":[540],"febrile":[541,566],"(42.1%),":[543,568],"diarrhea":[544],"(41.1%),":[545],"anemia":[546,570],"(39.3%),":[547],"vomiting":[548],"(36.4%),":[549],"hypokalemia":[551],"(26.2%).":[552],"reported":[556,574],"\u226520%":[558],"(43.0%),":[565],"(34.6%).":[571],"Infections":[572],"57%":[576],"SAEs":[580],"40.2%":[582],"Of":[585],"59":[587],"deaths":[588,611],"(55.1%)":[589],"reported,":[590],"23":[591],"(21.5%)":[592],"due":[594],"disease":[596],"progression":[597],"7":[599,610],"(6.5%)":[600,612],"events.":[603],"Within":[604],"60":[605],"days":[606,621],"after":[607],"start,":[609],"reported.":[614],"Conclusion:":[615],"14":[620],"plus":[622],"well":[626],"tolerated":[627],"favorable":[629],"CR+PR+mCR":[632],">80%":[634],"HI":[636],"nearly":[638],"50%":[639],"treatment-na\u00efve":[643],"A":[646],"separate":[647],"3":[649],"this":[652],"is":[654],"ongoing":[655],"confirm":[657],"benefit.":[659]},"counts_by_year":[{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":7}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2023-12-02T00:00:00"}